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The American College of Cardiology-American Heart Association Committee recommends
first line beta-adrenergic blocking agents for chronic stable effort angina. This article
reassesses some critical evidence that is new or could have been neglected by the Committee.
In particular, the putative role of calcium channel blocking agents (CCBs) is reexamined.
Additional evidence is culled from articles not cited by the Committee, together with added
reference to recent trials. Safety, side-effects and tolerability are issues that are evaluated.
Mortality data are reviewed with the aid of a meta-analysis of all placebo-controlled trials on
long acting CCBs. The advice of the committee may need to be reconsidered in view of recent
evidence on the tolerability and benefits in hypertension of newer, longer-acting, second-
generation CCBs. Of the older agents, verapamil has been shown to be the best with regard
to safety and efficacy. Especially in the elderly, angina is often associated with hypertension,
with evidence showing dihydropyridine CCBs and beta-adrenergic blocking agents to be
similarly effective. Beta-blockers may have undesirable side effects such impotence and
impaired exercise ability, despite their proven protective effects in postinfarct patients and in
heart failure. The choice of drug should be keyed to the needs and the pathophysiology of the
individual patient. (J Am Coll Cardiol 2000;36:1967–71) © 2000 by the American College
of Cardiology
Americans are prone to believe the advice of institutional
authorities.
John Seabrook,
New Yorker, Nov 8, 1999.
Recently the American College of Cardiology/American
Heart Association (ACC/AHA) guidelines for the treat-
ment of chronic angina strongly suggested that beta-
adrenergic blocking agents should be the agents of first
choice in the management of angina, both in the text and in
an accompanying eye-catching diagram (1). The ACC/
AHA guidelines base their preference for beta-blocker
therapy on two pieces of evidence: first, the proven life-
saving qualities of beta-blockers in postinfarct patients,
which leaves open the question of how to handle those who
are not postinfarct, and, second, by extrapolation from the
supposed effects of these agents in hypertension, where the
guidelines believe that beta-blockers, but not calcium chan-
nel blockers (CCBs), reduce mortality. I agree with the first
of these statements, but otherwise I believe that the advice
is overstated. The guidelines are largely based on clinical
trial data from the 1980 to the early 1990 eras and do not
adequately take into account evidence from the newer
long-acting CCBs as exemplified by amlodipine. Among
the older agents, the guidelines also do not sufficiently
acknowledge that verapamil gives postinfarct protection.
I shall argue that the evidence is that: 1) Both beta-
blockers and CCBs are equally effective as antianginals. 2)
Regarding mortality in chronic effort angina, beta-blockers
reduce mortality in postinfarct and heart failure patients, but
there are no data showing that either beta-blockers or CCBs
reduce mortality in chronic effort angina. 3) In hypertension
beta-blockers and new generation CCBs are equally effec-
tive in reducing hard end points. 4) There is no good
evidence to show that beta-blockers are better tolerated than
the newer CCBs, with a suggestion of the reverse if
amlodipine were to be considered. Finally I shall provide
evidence for the long-term safety of long-acting CCBs. At
the same time, it must be acknowledged that there have
been serious problems with the early generation and short-
acting CCBs, specifically with instant-release nifedipine
(2,3).
Situations in which beta-blockers are clearly the first
choice. There are two such situations in which beta-
blockers are clearly the first choice, as will be argued. The
first of those situations would be in postinfarct patients, and
the second would be in those with overt heart failure. Only
the former situation is considered in the guidelines.
Postinfarct beta-blockers versus CCBs. After infarction
and in the prestatin era, the incidence of effort angina varied
from about 20% to 55% (4). There is increasing evidence
that beta-blockers give postinfarct protection with a mor-
tality reduction, coming both from meta-analyses of ran-
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domized trials (5) and from observational studies (6). The
percentage reduction in death is about 23% in prospective
trials (5) and up to 40% in observational studies (6). For
CCBs the postinfarct data are much more limited. Only
with verapamil and nisoldipine have there been randomized
controlled trials. In the case of verapamil, most of the data
come from the DAVIT II study (7). The recent meta-
analysis of Pepine et al. (8) shows that postinfarct verapamil
only gives a small and nonsignificant reduction in mortality
of about 10%, while bringing down the combined end point
of death or reinfarction by 18%. Furthermore, verapamil
specifically reduces angina after myocardial infarction at 18
months of follow-up (4). In a large observational trial on
141,041 elderly postinfarct patients, none of the CCBs
tested (nifedipine, diltiazem, verapamil, amlodipine) in-
creased one-year mortality compared with the results for
non-CCB users, so that CCBs can be used to treat
postinfarct angina without altering mortality (9). In the case
of nisoldipine, when given to postinfarct patients with a
mean ejection fraction of 40% but without clinical heart
failure, there was a modest antianginal effect with an
increased time to 1 mm ST deviation (10). There was a
trend towards mortality reduction, but the trial was not
adequately powered. However, it is only verapamil (not just
any CCB) that has prospective randomized trial data in its
favor, so that it becomes the agent of choice when beta-
blockade is contraindicated or not tolerated. Therefore, the
guidelines of the ACC/AHA give good advice on postin-
farct patients with effort angina; use beta-blockers whenever
possible.
Heart failure with angina. When treating heart failure with
angina, an important aim is to treat the heart failure as well as
possible, as left ventricular cavity dilation increases the myo-
cardial oxygen demand. Increasingly, beta-blockers are being
used in heart failure, now on the basis of trials showing a clear
mortality reduction (11,12). About half the patients in these
trials had ischemic heart failure, so that the percent with angina
must have been relatively high although not stated. Regarding
calcium antagonists, in the Prospective Randomized Amlodip-
ine Survival Evaluation (PRAISE) (13), amlodipine did not
improve mortality in the subgroup with angina, whereas it did
in the subgroup with hypertension. Only if there is persistent
hypertension despite the combined use of diuretics, an
angiotensin-converting enzyme (ACE) inhibitor and a beta-
blocker, is there a good case for adding a CCB. At present in
the U.S. there is only one beta-blocker that is licensed for heart
failure, and that is carvedilol. In the U.K., but not in the U.S.,
it is also licensed for angina.
Evidence from hypertension: the agents are equal. “Beta-
blockers reduce mortality and morbidity among patients
with hypertension,” according to the ACC/AHA Guide-
lines. This statement is widely quoted but is not necessarily
accurate. In fact the analysis by Psaty and Curt Furberg as
published in JNC VI shows that beta-blockers do not
reduce mortality in hypertension, nor do these agents reduce
coronary heart disease although they do reduce stroke and
heart failure (14). In the Controversies series in the Journal
of the American Medical Association, Psaty et al. (15) state
that drug treatment with beta-blocker therapy has thus far
failed to prevent coronary heart disease (CHD). This
opinion confirms that of Hansson in 1987, that “three large
trials have failed to show a beta-blocker-derived protective
effect against CHD in hypertensive patients” (16). There
have been only a few head-to-head comparisons of beta-
blockers versus low-dose diuretics in hypertension. For
example, in the Medical Research Council trial of hyper-
tension in the elderly, beta-blockers were no better than
placebo in preventing coronary disease, whereas low-dose
diuretics were effective (17). The earlier Medical Research
Council trial on younger patients showed equal effects on
coronary disease of these two types of agents but used high-
rather than low-dose diuretics. High-dose diuretics as a
group do not protect against coronary disease (14). Another
trial, sometimes quoted to support an effect of beta-blockers
on coronary disease in hypertensives (18), compared beta-
blockers with all nonbeta-blocker therapies (19). In fact,
total diuretic use was high in both groups, being 67% in the
beta-blocker and 82% in the nonbeta-blocker group.
Calcium channel blockers, on the other hand, have
evidence in their favor, being specifically effective in reduc-
ing all major cardiac events and angina in elderly patients
with systolic hypertension although without any effect on
mortality, except in the diabetic subgroup (20,21).
However, such indirect comparisons are imperfect, and the
gold standard in reaching valid conclusions is a randomized
controlled trial. Swedish Trial in Old Patients (STOP) 2 is a
landmark trial on 6,614 hypertensive patients (22). It compares
outcome data over a mean of five years in this advanced age
population (average: 76 years), CCBs and conventional therapy
(diuretics or beta-blockers or both). Therefore, it is blood
pressure reduction, per se, which is overriding in conferring
benefit, not the agent initially chosen. Of note though, the
CCBs used were long-acting preparations of felodipine and
isradipine, not amlodipine. Nonetheless, the principle of dihy-
dropyridine (DHP) CCBs having equal effects on mortality as
conventional agents is likely to hold for the long-acting DHPs
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that were not tested. Thus, presently available hypertension
trials with new information on the DHP-type CCBs provide
no reason for the prior choice of beta-blockers over CCBs, as
argued by the Guidelines.
The Stanford meta-analysis: does tolerability tip the
scales? These ACC/AHA recommendations are based on
the same trials that are summarized in the meta-analysis from
Stanford (23). This meta-analysis proposes equal antianginal
efficacy and equal safety for the two types of agents. Regarding
efficacy, beta-blockers were borderline better at reducing angi-
nal attacks, and CCBs were better at prolonging the exercise
time, but the statistics were marginal with p 5 0.05 in each
case, and nitrate use was similar. Given this virtual equality, the
meta-analysis goes on to claim that beta-blockers become the
agents of choice because they were better tolerated. However,
this judgement is based largely on the poor tolerability of
nifedipine, especially in the short-acting form. Figure 4 of the
meta-analysis illustrates these points (23). The better tolera-
bility of a beta-blocker at equal antianginal efficacy is also
confirmed in a more recent trial that compared felodipine with
metoprolol (24).
Yet with amlodipine the situation may be different. Its
binding site to the calcium channel has unique properties when
compared with all the other DHPs (25). It has slower onset
and offset kinetics and a much longer inherent half-life than
other CCBs. In a large hypertension trial over four years,
amlodipine was the best tolerated of the agents compared with
an alpha-blocker, a beta-blocker, a diuretic and an ACE-
inhibitor (26). In three relatively small comparative studies
with beta-blockers, amlodipine was better tolerated (27–29). In
the Prospective Randomized Evaluation of the Vascular Ef-
fects of Norvasc Trial (PREVENT), amlodipine given to
patients with coronary angiographic disease had reduced out-
come measures after three years (30). In the Coronary Angio-
Plasty REStenosis Study (CAPARES) (31), amlodipine was
started 2 weeks before percutaneous transluminal coronary
angioplasty and reduced repeat percutaneous transluminal
coronary angioplasty and composite major clinical events. Such
data do not exist for beta-blockers.
Verapamil and diltiazem are known to be well-tolerated,
except for constipation with verapamil. However, diltiazem,
in my view, lacks the same outcome data that verapamil has,
and there is some indication that it is not as safe as
verapamil (32). Verapamil gives a better overall quality of
life than does propranolol (33). As noted in the Guidelines,
beta-blockers are the cause of several side-effects such as
fatigue, impaired exercise ability and erectile dysfunction.
The latter is especially undesirable because it may lead to the
use of Viagra, with the real risk of dangerous interactions
with nitrates. Only atenolol, and not long-acting nifedipine,
reduced testosterone levels over 24 weeks, and this agent
gave more sexual dysfunction (34). In another study with
sexual intercourse as an end point, atenolol caused a sus-
tained depression (35). In a four-year study on mildly
hypertensive middle-aged men, amlodipine gave no more
sexual problems than did placebo (36). The beta-blocker
used in that study, acebutolol, was atypical in that it has
intrinsic sympathomimetic activity and is not licensed for
use in angina in the U.S., so that direct comparisons with
amlodipine cannot be made.
Safety issues: mortality studies. Ever since the adverse
meta-analysis of Furberg et al. (2), the CCBs have been
under a cloud. It is often forgotten that, as originally
published, there were considerable arithmetical errors in the
tables, that all the studies focussed on short-acting nifedi-
pine or nicardipine and that the links to mortality were at
doses of short-acting nifedipine of more than 80 mg per
day. Since then the mortality risk for CCBs as a group has
been discounted by observational studies, showing either the
safety of long-acting CCBs (37) or the neutrality of CCBs
in hypertension when compared with other agents, as in the
Framingham study (38). There are good data from an
important observational study in the very elderly showing
that, from the mortality point of view, even short acting
verapamil is as safe as beta-blockade, whereas short-acting
nifedipine is associated with an increased mortality, with
short-acting diltiazem somewhere in between (32). Phar-
macokinetically, short-acting verapamil has a long-acting
metabolite, norverapamil, so that it actually falls into the
category of medium- or long-acting CCB (39).
Beta-blockers also have not been without safety prob-
lems. In prospective observational study on 12,550 hyper-
tensive patients over six years, those taking beta-blockers
had a 28% higher risk of developing diabetes, whereas those
taking CCBs had no increase in that risk (40).
To examine the mortality risk, I have grouped all the studies
that I could find in which a medium- or long-acting CCB was
compared with placebo and in which there was a cardiovascular
end point (Table 1). From this point of view, “short” acting
verapamil is regarded as having a medium or long duration of
action (39). I have excluded the studies reported by Furberg et
al. (2), which all relate to short acting DHPs, chiefly capsular
nifedipine. The result is that there is a total mortality reduction
of 20% (p 5 0.012). If two studies from China are included,
being placebo-controlled, although using sequential rather
than random allocation, then the reduction in mortality is 23%
with p , 0.001. These conclusions must be tempered with
reservation because of the heterogeneous nature of the trials
grouped together. Yet the overall message is that mortality
tends to decrease rather than increase, contrary to the original
proposal in the meta-analysis that focused on short-acting
nifedipine (2).
Caveats. Practice in the management of CHD is rapidly
changing with the widespread use of statins and now prophy-
lactic ACE inhibitors, as well as increasing percutaneous
interventions under cover of the new platelet glycoprotein
IIb/IIIa receptor blockers. Furthermore, a Mediterranean diet
can reduce total postinfarct mortality (41). The demographics
of angina are also changing with a greater number of elderly
patients, often hypertensive and sometimes diabetic, in whom
CCBs, but not beta-blockers, have evidence in their favor in
placebo-controlled trials (17,20,21). There is an increasing
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emphasis on global risk factor prevention including blood
pressure control, aggressive lipid lowering, dietary and lifestyle
changes. Against this background, current comparisons be-
tween beta-blockers and CCBs must necessarily rest on infor-
mation already gathered, when overall practice in effort angina
was different. Thus, prospective, properly powered, random-
ized trials between these agents are ideally required in this new
era.
Another important issue is cost. The newer generation
CCBs are, on the whole, relatively expensive. By contrast,
generic verapamil or diltiazem or metoprolol or atenolol are
relatively cheap.
Proposal. Therefore, I feel that an open mind should be
kept and that there are equal arguments for either beta-
blockers or CCBs in chronic effort angina, providing that
there is neither prior infarction nor current heart failure.
Rather, the choice can be made depending on the patient
and the heart. Thus, in an active middle-aged man in whom
the quality of life must be preserved and for whom exercise
training and preserved sexual function are important, there
are good arguments for starting with a well-tolerated CCB
such as amlodipine or one of the non-DHPs. For predom-
inant ischemia, the combination of a long-acting DHP with
a beta-blocker (27,42) or long-acting verapamil might be
better (43). For a black hypertensive patient with angina and
proteinuria, a beta-blocker is better (African American
Study of Kidney Disease). It is reassuring that the CCBs, as
a group, do not adversely affect all-cause mortality when
compared with placebo (44–53) nor when compared with
beta-blocker-diuretic therapy in hypertension, but, in a
patient with impaired regional contraction and a depressed
ejection fraction, such considerations get overridden, and
beta-blockers become the agents of choice.
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